Infección por el virus del papiloma humano (HPV) carcinogénico

Referencias

1 Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papilomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
2 Steben M, Duarte-Franco E. Human papilomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007;107:S2-5.
3 Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term persistence of human papilomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009;339:b2569.
4 Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papilomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
5 Ronco G, Arbyn M, Segnan N. Cervical screening according to age and HPV status. BMJ 2009;339:b3005.
6 Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk R. Natural history of cervicovaginal papilomavirus infection in young women. N Eng J Med 1998;338:423-8.
7 Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S, et al. Early natural history of incident, type-specific human papilomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011;20:699-707.
8 Harper DM, Franco EL, Wheeler C, Moscicki A-B, Romanowski B, Roteli-Martins C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
9 Romanowski B. Long term protection against cervical infection with the human papilomavirus: review of currently available vaccines. Hum Vaccin 2011;7:161-9.
10 Brabin L, Roberts S, Stretch R, Baxter D, Chambers G, Kitchener H, et al. Uptake of first two doses of human papilomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008;336:1056-8.
11 Moser K, Patnick J, Beral V. Inequalities in reported use of breast and cervical screening in Great Britain: analysis of cross sectional survey data. BMJ 2009;338:b2025.
12 Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010;340:c1642.
13 Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, et al. Is Mycoplasma genitaliium in women the “new chlamydia”? Community-based prospective cohort study. Clin Infect Dis 2010;51:1160-6.
14 Howell-Jones R, de Silva N, Akpan M, Carder C, Ellis V, Frodsham D. Prevalence of human papilomavirus (HPV) infections in sexually active adolescents and young women in England prior to widespread HPV immunisation. Vaccine 2012: in press.
15 Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010;103:209-16.
16 Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol 2009;10:321-2.
17 Kim S, Arduino JM, Roberts CC, Marsico M, Liaw KL, Skjeldestad FE. Incidence and predictors of human papilomavirus-6, -11, -16, and -18 infection in young Norwegian women. Sex Transm Dis 2011;38:1-9.
18 Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat N, Koutsky L. Genital human papilomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
19 Sinka K, Lacey M, Robertson C, Kavanagh K, Cuschieri K, Nicholson D, et al. Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring. Sex Transm Infect 2011;87:548-52.
20 Winer RL, Feng Q, Hughes J, Yu M, Kiviat N, O’Reilly S, et al. Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis 2007;34:371-7.
21 Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008;98:1704-9.
22 Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papilomavirus infection in men (HIM): a cohort study. Lancet 2011;377:932-40.
23 Winer RL, Hughes J, Feng Q, O’Reilly S, Kiviat N, Holmes KK, et al. Condom use and risk of genital human papilomavirus infection in young women. N Eng J Med 2006;354:2645-54.
24 Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M, Wheeler CM, et al. Predictors of human papilomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010;126:684-91.
25 Verheijen RHM. Comparing bivalent and quadrivalent HPV vaccines. BMJ 2011;343:d5720. 26 Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papilomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a
double-blind, randomised study in young women. Lancet 2009;374:301-14.
27 Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011;11:13.
28 Garnett G, Kim J, French K, Goldie S. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine . 24th ed. Elsevier, 2006:178-86. Accepted: 08 May 2012